person · Reporting owner

Zakrzewski Joseph S

Disclosed activity across 6 companies

Tapewire entity: 23401
SEC CIK: 0001331852

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMARIN CORP PLC\UKAMRN · Entity 5970	Director	December 14, 2021	December 17, 2021
AN2 Therapeutics, Inc.ANTX · Entity 1085	Director	August 14, 2026	August 14, 2026
Cyteir Therapeutics, Inc.CYT · Entity 92707	Director	February 06, 2024	February 08, 2024
INSULET CORPPODD · Entity 3516	Director	May 17, 2017	May 18, 2017
SANGAMO THERAPEUTICS, INCSGMO · Entity 7038	Director	February 25, 2022	March 01, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMARIN CORP PLC\UK

Report date December 14, 2021 · Filed December 17, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	194,547	Reported balance After 2021-12-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-12-14 · Purchase · Acquired 10,000 · Balance 194,547 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Ordinary SharesSEC Table I · non-derivative	Direct	196,547	Reported balance After 2021-12-15 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2021-12-15 · Purchase · Acquired 2,000 · Balance 196,547 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Please see the section titled "Remarks" below for additional information.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Please see the section titled "Remarks" below for additional information.

AN2 Therapeutics, Inc.

Report date August 14, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2026-08-14 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-08-14 · Gift · Disposed 405,880 · Balance 0 F1: Reflects a gift of shares to the children of the Reporting Person. F2: The shares are held by Nancy Zakrzewski TTEE Z3 Trust U/A DTD 11/25/14 ("Z3 Trust"). The Reporting Person disavows beneficial ownership of the shares held by Z3 Trust.
Common StockSEC Table I · non-derivative	Direct	145,538	Reported balance Holding disclosure · report date 2026-08-14 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 145,538

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a gift of shares to the children of the Reporting Person.

F2: The shares are held by Nancy Zakrzewski TTEE Z3 Trust U/A DTD 11/25/14 ("Z3 Trust"). The Reporting Person disavows beneficial ownership of the shares held by Z3 Trust.

Cyteir Therapeutics, Inc.

Report date February 06, 2024 · Filed February 08, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	227,439	Reported balance After 2024-02-06 transaction · row 1 1 source row Row 1 · 2024-02-06 · Exercise / conversion · Acquired 14,150 · Balance 227,439
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03	Direct	0	Reported balance After 2024-02-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-06 · Exercise / conversion · Disposed 14,150 · Balance 0
Common StockSEC Table I · non-derivative	IndirectSee Footnote	149,051	Reported balance Holding disclosure · report date 2024-02-06 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 149,051 F1: Shares held by Z3 Trust, of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Shares held by Z3 Trust, of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.

INSULET CORP

Report date May 17, 2017 · Filed May 18, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,558	Reported balance After 2017-05-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-05-17 · Grant · Acquired 2,709 · Balance 30,558 F1: The 2,709 restricted stock units vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F2: Includes 1,010 restricted stock units granted on May 13, 2015, which vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.60 · Expires 2027-05-17	Direct	3,587	Reported balance After 2017-05-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-05-17 · Grant · Acquired 3,587 · Balance 3,587

Filing footnotes · ownership attribution and instrument terms

F1: The 2,709 restricted stock units vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.

F2: Includes 1,010 restricted stock units granted on May 13, 2015, which vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.

SANGAMO THERAPEUTICS, INC

Report date February 25, 2022 · Filed March 01, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	60,700	Reported balance After 2022-02-25 transaction · row 1 1 source row Row 1 · 2022-02-25 · Grant · Acquired 12,500 · Balance 60,700 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2032-02-24	Direct	25,000	Reported balance After 2022-02-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-02-25 · Grant · Acquired 25,000 · Balance 25,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACCELERON PHARMA INC

Report date November 19, 2021 · Filed November 22, 2021

Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-11-19 transaction · row 1 1 source row Row 1 · 2021-11-19 · Other · Disposed 34,499 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $27.97	Direct	Reported balance After 2021-11-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-11-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $30.17	Direct	Reported balance After 2021-11-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-11-19 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $40.61	Direct	Reported balance After 2021-11-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-11-19 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.20	Direct	Reported balance After 2021-11-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-11-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64	Direct	Reported balance After 2021-11-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-11-19 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99	Direct	Reported balance After 2021-11-19 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-11-19 · Disposition to issuer · Disposed 8,185 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53	Direct	Reported balance After 2021-11-19 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-11-19 · Disposition to issuer · Disposed 3,222 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 14, 2026 Filed Aug 14, 2026 18:12 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	GiftCommon Stock	405,880	$0.00	$0.00	Disclosure SEC source: 0001193125-26-351801 · ownership.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Reflects a gift of shares to the children of the Reporting Person. F2 · ownership.nature: The shares are held by Nancy Zakrzewski TTEE Z3 Trust U/A DTD 11/25/14 ("Z3 Trust"). The Reporting Person disavows beneficial ownership of the shares held by Z3 Trust. Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:07 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	Disposition to issuerStock Option (right to buy) · Derivative	23,742	Not disclosed Strike: $5.91	Not disclosed	Disclosure SEC source: 0001193125-26-120214 · ownership.xml · derivative · entry 6 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:07 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	GrantStock Option (right to buy) · Derivative	23,742	Not disclosed Strike: $3.91	Not disclosed	Disclosure SEC source: 0001193125-26-120214 · ownership.xml · derivative · entry 5 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:07 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	Disposition to issuerStock Option (right to buy) · Derivative	10,362	Not disclosed Strike: $17.28	Not disclosed	Disclosure SEC source: 0001193125-26-120214 · ownership.xml · derivative · entry 4 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:07 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	GrantStock Option (right to buy) · Derivative	10,362	Not disclosed Strike: $3.91	Not disclosed	Disclosure SEC source: 0001193125-26-120214 · ownership.xml · derivative · entry 3 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,362 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:07 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	Disposition to issuerStock Option (right to buy) · Derivative	99,999	Not disclosed Strike: $6.60	Not disclosed	Disclosure SEC source: 0001193125-26-120214 · ownership.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,999 shares Expires 2031-04-29 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
March 19, 2026 Filed Mar 23, 2026 23:07 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	GrantStock Option (right to buy) · Derivative	99,999	Not disclosed Strike: $3.91	Not disclosed	Disclosure SEC source: 0001193125-26-120214 · ownership.xml · derivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,999 Underlying: Common Stock · 99,999 shares Expires 2031-04-29 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
February 20, 2026 Filed Feb 23, 2026 21:11 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	GrantStock Option (Right to Buy) · Derivative	20,400	$0.00 Strike: $1.04	$0.00	Disclosure SEC source: 0001193125-26-063984 · ownership.xml · derivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2036-02-19 F1 · derivative.exercise_date: The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date. Read SEC document
May 22, 2025 Filed May 23, 2025 20:58 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	GrantStock Option (Right to Buy) · Derivative	19,111	$0.00 Strike: $1.19	$0.00	Disclosure SEC source: 0000950170-25-077061 · ownership.xml · derivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,111 Underlying: Common Stock · 19,111 shares Expires 2035-05-21 F1 · derivative.exercise_date: The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document
April 10, 2025 Filed Apr 11, 2025 21:08 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	GrantCommon Stock	10,523	$0.00	$0.00	Disclosure SEC source: 0000950170-25-053373 · ownership.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,538 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document
December 19, 2024 Filed Dec 23, 2024 23:33 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	GrantCommon Stock	9,816	$0.00	$0.00	Disclosure SEC source: 0000950170-24-139793 · ownership.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,015 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document
November 27, 2024 Filed Nov 27, 2024 21:16 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	PurchaseCommon Stock	2,000	$1.40	$2,800.00	Disclosure SEC source: 0000950170-24-131499 · ownership.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,199 Read SEC document
November 19, 2024 Filed Nov 20, 2024 21:11 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	PurchaseCommon Stock	5,000	$1.01	$5,050.00	Disclosure SEC source: 0000950170-24-129248 · ownership.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,199 Read SEC document
November 18, 2024 Filed Nov 20, 2024 21:11 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	PurchaseCommon Stock	20,000	$1.00	$19,996.00	Disclosure SEC source: 0000950170-24-129248 · ownership.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,199 Read SEC document
June 19, 2024 Filed Jun 21, 2024 22:12 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	GrantStock Option (Right to Buy) · Derivative	64,503	$0.00 Strike: $2.00	$0.00	Disclosure SEC source: 0000950170-24-076399 · ownership.xml · derivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,503 Underlying: Common Stock · 64,503 shares Expires 2034-06-18 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document
February 06, 2024 Filed Feb 8, 2024 16:11 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	Exercise / conversionStock Option (Right to Buy) · Derivative	14,150	$0.00 Strike: $1.69	$0.00	Disclosure SEC source: 0001209191-24-002992 · doc4.xml · derivative · entry 3 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,150 shares Expires 2033-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 06, 2024 Filed Feb 8, 2024 16:11 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	Exercise / conversionCommon Stock	14,150	$1.69	$23,913.50	Disclosure SEC source: 0001209191-24-002992 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 18, 2024 Filed Jan 20, 2024 00:32 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	SaleCommon Stock	100,000	$19.11	$1,911,410.00	Disclosure SEC source: 0000950170-24-005900 · ownership.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 405,880 F1 · ownership.nature: These shares are held by Z3 Trust, for which the Reporting Person is a trustee. Read SEC document
June 07, 2023 Filed Jun 10, 2023 00:57 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	GrantStock Option (right to buy) · Derivative	23,742	$0.00 Strike: $5.91	$0.00	Disclosure SEC source: 0000899243-23-015321 · doc4.xml · derivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document
February 03, 2023 Filed Feb 7, 2023 16:48 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	GrantStock Option (Right to Buy) · Derivative	14,150	$0.00 Strike: $1.69	$0.00	Disclosure SEC source: 0001209191-23-007560 · doc4.xml · derivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,150 Underlying: Common Stock · 14,150 shares Expires 2033-02-03 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date. Read SEC document
December 07, 2022 Filed Dec 8, 2022 17:09 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	PurchaseCommon Stock	21,202	$1.30	$27,562.60	Disclosure SEC source: 0001209191-22-060377 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,618 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $1.28 to $1.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · balance_after: 27,551 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest. Read SEC document
May 12, 2022 Filed May 17, 2022 01:11 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	GrantStock Option (right to buy) · Derivative	10,362	$0.00 Strike: $17.28	$0.00	Disclosure SEC source: 0000899243-22-018273 · doc4.xml · derivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,362 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/12 of the shares shall vest on each monthly anniversary as measured from March 25, 2022. Read SEC document
May 12, 2022 Filed May 16, 2022 16:24 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	PurchaseCommon Stock	743	$1.61	$1,196.23	Disclosure SEC source: 0001209191-22-029135 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,416 F1 · balance_after: 55,102 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest. Read SEC document
May 11, 2022 Filed May 12, 2022 16:35 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	PurchaseCommon Stock	1,000	$1.70	$1,700.00	Disclosure SEC source: 0001209191-22-028574 · doc4.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,673 F2 · balance_after: 55,102 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest. Read SEC document
May 10, 2022 Filed May 12, 2022 16:35 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	PurchaseCommon Stock	49,406	$1.89	$93,377.34	Disclosure SEC source: 0001209191-22-028574 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,673 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $1.67 to $2.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · balance_after: 55,102 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest. Read SEC document
March 29, 2022 Filed Apr 1, 2022 00:15 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	ConversionSeries A Convertible Preferred Stock · Derivative	98,199	$0.00	$0.00	Disclosure SEC source: 0000899243-22-012992 · doc4.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98,199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. Read SEC document
March 29, 2022 Filed Apr 1, 2022 00:15 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	ConversionCommon Stock	98,199	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-012992 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:15 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $5.90	$0.00	Disclosure SEC source: 0001209191-22-014161 · doc4.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-24 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:15 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	12,500	$0.00	$0.00	Disclosure SEC source: 0001209191-22-014161 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,700 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
February 22, 2022 Filed Feb 24, 2022 17:03 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	GrantStock Option (Right to Buy) · Derivative	14,150	$0.00 Strike: $5.96	$0.00	Disclosure SEC source: 0000899243-22-007653 · doc4.xml · derivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,150 Underlying: Common Stock · 14,150 shares Expires 2032-02-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on February 22, 2023, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date. Read SEC document
December 28, 2021 Filed Dec 28, 2021 18:24 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	PurchaseCommon Stock	601	$9.85	$5,919.85	Disclosure SEC source: 0000899243-21-049973 · doc4.xml · nonDerivative · entry 4 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,267 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $9.81 to $9.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F1 · balance_after: 79,932 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest. Read SEC document
December 27, 2021 Filed Dec 28, 2021 18:24 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	PurchaseCommon Stock	99	$10.18	$1,007.82	Disclosure SEC source: 0000899243-21-049973 · doc4.xml · nonDerivative · entry 3 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,666 F1 · balance_after: 79,932 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest. Read SEC document
December 27, 2021 Filed Dec 28, 2021 18:24 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	PurchaseCommon Stock	200	$9.97	$1,994.00	Disclosure SEC source: 0000899243-21-049973 · doc4.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,567 F1 · balance_after: 79,932 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest. Read SEC document
December 23, 2021 Filed Dec 28, 2021 18:24 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	PurchaseCommon Stock	200	$9.87	$1,974.00	Disclosure SEC source: 0000899243-21-049973 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,367 F1 · balance_after: 79,932 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest. Read SEC document
December 17, 2021 Filed Dec 21, 2021 18:06 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	PurchaseCommon Stock	200	$9.88	$1,976.00	Disclosure SEC source: 0000899243-21-049198 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,167 F1 · balance_after: 84,523 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest. Read SEC document
December 15, 2021 Filed Dec 15, 2021 20:09 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	PurchaseCommon Stock	1,700	$11.12	$18,904.00	Disclosure SEC source: 0000899243-21-048432 · doc4.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,967 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $10.95 to $11.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · balance_after: 84,523 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest. Read SEC document
December 15, 2021 Filed Dec 15, 2021 20:09 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	PurchaseCommon Stock	2,000	$10.47	$20,940.00	Disclosure SEC source: 0000899243-21-048432 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,267 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $9.95 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · balance_after: 84,523 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest. Read SEC document
December 15, 2021 Filed Dec 17, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	PurchaseOrdinary Shares	2,000	$3.16	$6,310.00	Disclosure SEC source: 0001562180-21-007737 · primarydocument.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,547 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
December 14, 2021 Filed Dec 17, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	PurchaseOrdinary Shares	10,000	$3.27	$32,689.00	Disclosure SEC source: 0001562180-21-007737 · primarydocument.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,547 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:12 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	3,222	Not disclosed Strike: $115.53	Not disclosed	Disclosure SEC source: 0001104659-21-142280 · tm2133601-13_4seq1.xml · derivative · entry 8 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,222 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:12 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	8,185	Not disclosed Strike: $52.99	Not disclosed	Disclosure SEC source: 0001104659-21-142280 · tm2133601-13_4seq1.xml · derivative · entry 7 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,185 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:12 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	7,500	Not disclosed Strike: $41.64	Not disclosed	Disclosure SEC source: 0001104659-21-142280 · tm2133601-13_4seq1.xml · derivative · entry 6 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:12 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	10,000	Not disclosed Strike: $41.20	Not disclosed	Disclosure SEC source: 0001104659-21-142280 · tm2133601-13_4seq1.xml · derivative · entry 5 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:12 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	7,500	Not disclosed Strike: $40.61	Not disclosed	Disclosure SEC source: 0001104659-21-142280 · tm2133601-13_4seq1.xml · derivative · entry 4 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:12 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	7,500	Not disclosed Strike: $30.17	Not disclosed	Disclosure SEC source: 0001104659-21-142280 · tm2133601-13_4seq1.xml · derivative · entry 3 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:12 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Disposition to issuerOption to Purchase Common Stock · Derivative	10,000	Not disclosed Strike: $27.97	Not disclosed	Disclosure SEC source: 0001104659-21-142280 · tm2133601-13_4seq1.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document
November 19, 2021 Filed Nov 22, 2021 09:12 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherCommon Stock	34,499	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-142280 · tm2133601-13_4seq1.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document
June 22, 2021 Filed Jun 24, 2021 20:54 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	ConversionSeries B Convertible Preferred Stock · Derivative	200,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-025827 · doc4.xml · derivative · entry 4 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 58,671 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by Z Investments, LLC, of which the Reporting Person is the Managing Director. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein. Read SEC document
June 22, 2021 Filed Jun 24, 2021 20:54 UTC	Cyteir Therapeutics, Inc. CYT · Entity 92707	ConversionCommon Stock	58,671	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-025827 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 58,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by Z Investments, LLC, of which the Reporting Person is the Managing Director. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein. Read SEC document
June 14, 2021 Filed Jun 17, 2021 00:07 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantRestricted Stock Units · Derivative	36,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-21-004331 · primarydocument.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Ordinary Shares · 36,000 shares Expires not disclosed F3 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On June 14, 2021, the Reporting Person was granted 36,000 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 14, 2021 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.